Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.


CSE:SONA - Post by User

Comment by oxinoson Oct 23, 2020 2:23pm
136 Views
Post# 31771958

RE:RE:RE:RE:RE:RE:RE:when it happnes

RE:RE:RE:RE:RE:RE:RE:when it happnesDarren Rowles was the CEO but relinquished this position when David Regan was appointed as CEO for a sx month period as per a News Release a while back. Darren Rowles has the title of Chief Scientific Officer for now. If you recall David Regan was appointed to help in the process of a Nasdac listing among other things.

"Halifax-based Sona Nanotech has announced that strategic adviser David Regan will replace Darren Rowles as CEO and that it will pursue a listing on the NASDAQ stock exchange in New York.

Sona has been a darling of the Canadian Securities Exchange since it said in March it would use its nanoparticle technology to develop rapid diagnostic kits for diseases that include COVID-19. The share price has soared since it said last week its coronavirus test would enter production with a “research use only” disclaimer as it sought approval from the Food and Drug Administration and Health Canada.

The company issued a statement late Wednesday saying that Regan, who has been working with the company for the past four months, will run the company in collaboration with Rowles, who now has the title President and Chief Scientific Officer."

<< Previous
Bullboard Posts
Next >>